Vyne Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

YARROW BIOSCIENCE

05/05/2025 14:17

Vyne Therapeutics Inc VYNE.OQ VYNE.O is expected to show a fall in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

The Bridgewater New Jersey-based  company is expected to report a 49.0% decrease in revenue to $50 thousand from $98 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Vyne Therapeutics Inc is for a loss of 29 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Vyne Therapeutics Inc is $5.50​, above​ its last closing price of $1.37. ​​​

This summary was machine generated May 5 at 13:17 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)